Development and Validation of an Immuno-PET Tracer as a CompanionDiagnostic Agent for Antibody-Drug Conjugate Therapy to Target the CA6Epitope

摘要

The antibody fragment ⁶⁴Cu-DOTA-B-Fab showed high binding affinity and stability and a promising ability to allow differentiation between CA6-positive and CA6-negative tumors in vivo at early time points after injection, suggesting that it may be a successful companion diagnostic agent for antibody-drug conjugate therapy.